Table 5.
Perceived concerns and barriers to prescribe PrEP among HIV physicians from Brazil and Mexico, 2020
| Total | Brazil | Mexico | P valuea | |
|---|---|---|---|---|
| (N = 481) n (%) |
(N = 339; 70.5%) n (%) |
(N = 142; 29.5%) n (%) |
||
| Concerns (yes) | ||||
| Consistent access to PrEP medication | 379 (78.6) | 281 (82.9) | 98 (68.3) | <.001 |
| ARVb resistance in case of acute HIV infection or seroconversion | 362 (75.1) | 243 (71.7) | 119 (83.2) | <.01 |
| Risky behavior increasal | 361 (74.9) | 238 (70.2) | 123 (86) | <.001 |
| Users need to take a drug everyday | 361 (74.9) | 255 (75.2) | 106 (74.1) | .80 |
| Risk of ARV drug resistance | 326 (67.6) | 215 (63.4) | 111 (77.6) | <.01 |
| Severe adverse effects | 270 (56) | 179 (52.8) | 91 (63.6) | .03 |
| Mild adverse effects | 204 (42.3) | 131 (38.6) | 73 (51.1) | .01 |
| Limited availability of ARV for people living with HIV | 266 (55.2) | 177 (52.2) | 89 (62.2) | .04 |
| PrEP efficacy | 177 (36.7) | 112 (33) | 65 (45.5) | .01 |
| Barriers (yes) | ||||
| Users have low PrEP knowledge | 298 (62.0) | 198 (58.4) | 100 (70.4) | .01 |
| Users have limited capacity for PrEP adherence | 284 (59.0) | 188 (55.5) | 96 (67.6) | .01 |
| Lack of professionals to prescribe PrEP | 276 (57.4) | 210 (62.0) | 66 (46.5) | <.01 |
| Limited time to discuss PrEP | 171 (35.6) | 111 (32.7) | 60 (42.3) | .05 |
| I have no knowledge about PrEP | 165 (34.3) | 89 (26.3) | 76 (53.5) | <.001 |
| I do not know where to refer a potential PrEP userc | 81 (16.8) | 81 (23.9) | – | N/Ad |
aChi-square test
bAntiretroviral
cThis question was not asked in Mexico as PrEP is not current public policy
dN/A Not applicable